FMP
Infinity Pharmaceuticals, Inc.
INFI
NASDAQ
Inactive Equity
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
0.008 USD
-0.0088 (-110%)
2022
2021
2020
2019
-42.43M
-40.62M
-35.74M
-41.53M
-44.37M
-45.26M
-40.49M
-47.06M
458k
480k
483k
219k
0
0
0
0
3.62M
2.69M
1.46M
2.13M
-1.04M
2.21M
1.39M
1.38M
0
0
0
0
0
0
0
0
-300k
2.18M
882k
1.55M
-739k
37k
503k
-167k
-1.1M
-745k
1.43M
1.79M
-55k
5.49M
14.63M
-12.24M
-17k
-11k
-43k
-2.33M
0
0
0
0
-16.04M
0
-43.01M
-41.86M
16M
5.5M
57.68M
31.95M
0
0
0
0
73k
87.11M
27.44M
27.73M
0
0
0
0
73k
87.11M
7.87M
112k
0
0
0
0
0
0
0
0
73k
87.11M
27.44M
27.73M
-42.45M
-40.63M
-35.78M
-43.86M
-42.43M
-40.62M
-35.74M
-41.53M
-17k
-11k
-43k
-2.33M
80.88M
28.91M
22.57M
48.62M
38.47M
80.88M
28.91M
22.57M
-42.41M
51.98M
6.33M
-26.04M
All figures are in USD.